Asunaprevir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326709

CAS#: 630420-16-5

Description: Asunaprevir, also known as BMS-650032, is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.

Chemical Structure

img
Asunaprevir
CAS# 630420-16-5
Instruction

Theoretical Analysis

MedKoo Cat#: 326709
Name: Asunaprevir
CAS#: 630420-16-5
Chemical Formula: C35H46ClN5O9S
Exact Mass: 747.27
Molecular Weight: 748.289
Elemental Analysis: C, 56.18; H, 6.20; Cl, 4.74; N, 9.36; O, 19.24; S, 4.28

Price and Availability

Size Price Availability Quantity
5mg USD 550 2 Weeks
10mg USD 950 2 Weeks
25mg USD 1650
Bulk inquiry

Synonym: BMS-650032; BMS 650032; BMS650032; Asunaprevir. brand name: Sunvepra

IUPAC/Chemical Name: 1,1-dimethylethyl ((1S)-1-{((2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl}carbamoyl) pyrrolidin-1-yl)carbonyl}-2,2-dimethylpropyl)carbamate

InChi Key: XRWSZZJLZRKHHD-WVWIJVSJSA-N

InChi Code: InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1

SMILES Code: O=C(OC(C)(C)C)N[C@H](C(N1[C@H](C(N[C@@]2(C(NS(=O)(C3CC3)=O)=O)[C@H](C=C)C2)=O)C[C@@H](OC4=NC=C(OC)C5=C4C=C(Cl)C=C5)C1)=O)C(C)(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 748.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hernandez D, Yu F, Huang X, Kirov S, Pant S, McPhee F. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Adv Ther. 2016 Jun 10. [Epub ahead of print] PubMed PMID: 27287851.

2: Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 2016 May 12;13(6):418-23. doi: 10.7150/ijms.15519. eCollection 2016. PubMed PMID: 27279790; PubMed Central PMCID: PMC4893555.

3: Sohda T, Yamauchi E, Anan A, Yokoyama K, Fukunaga A, Yamauchi R, Fukuda S, Takata K, Tanaka T, Hanano T, Kitamura Y, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res. 2016 Jun 4. doi: 10.1111/hepr.12758. [Epub ahead of print] PubMed PMID: 27260815.

4: Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2016 Jun 3. doi: 10.1002/jmv.24592. [Epub ahead of print] PubMed PMID: 27256744.

5: Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang JH, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2016 May 28. [Epub ahead of print] PubMed PMID: 27236547.

6: Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016 May 3. doi: 10.1111/hepr.12738. [Epub ahead of print] PubMed PMID: 27142311.

7: Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respir Investig. 2016 May;54(3):207-10. doi: 10.1016/j.resinv.2015.12.003. Epub 2016 Jan 18. PubMed PMID: 27108017.

8: Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis. Ther Apher Dial. 2016 Apr 21. doi: 10.1111/1744-9987.12407. [Epub ahead of print] PubMed PMID: 27098678.

9: Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R, Noviello S. All-oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016 Mar 24. doi: 10.1111/liv.13128. [Epub ahead of print] PubMed PMID: 27009831.

10: Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016 Mar 22. doi: 10.1111/jgh.13379. [Epub ahead of print] PubMed PMID: 27003037.

11: Matsumoto N, Ikeda H, Shigefuku R, Hattori N, Watanabe T, Matsunaga K, Hiraishi T, Tamura T, Noguchi Y, Fukuda Y, Ishii T, Okuse C, Sato A, Suzuki M, Itoh F. Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. PLoS One. 2016 Mar 18;11(3):e0151238. doi: 10.1371/journal.pone.0151238. eCollection 2016. PubMed PMID: 26990758; PubMed Central PMCID: PMC4798293.

12: Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases. 2016 Mar 16;4(3):88-93. doi: 10.12998/wjcc.v4.i3.88. PubMed PMID: 26989674; PubMed Central PMCID: PMC4792170.

13: Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Mar 7. [Epub ahead of print] PubMed PMID: 26948482.

14: Sato A, Ishii T, Adachi K, Kumon D, Tamura T, Noguchi Y, Matsumoto N, Okuse C. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy. Clin J Gastroenterol. 2016 Apr;9(2):89-92. doi: 10.1007/s12328-016-0630-2. Epub 2016 Feb 20. PubMed PMID: 26896968.

15: Uchida Y, Kouyama JI, Naiki K, Sugawarav K, Inao M, Imai Y, Nakayama N, Mochida S. Development of rare RAVs that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy Via a Two-Hit mechanism. Hepatol Res. 2016 Feb 15. doi: 10.1111/hepr.12673. [Epub ahead of print] PubMed PMID: 26878268.

16: Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Feb 12. [Epub ahead of print] PubMed PMID: 26872889.

17: Ozeki I, Nakajima T, Yamaguchi M, Kimura M, Arakawa T, Kuwata Y, Ohmura T, Sato T, Hige S, Karino Y, Toyota J. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy. Hepatol Res. 2016 Feb 9. doi: 10.1111/hepr.12667. [Epub ahead of print] PubMed PMID: 26857426.

18: Suzuki F. [Daclatasvir plus asunaprevir combination therapy for patients with chronic hepatitis C]. Nihon Rinsho. 2015 Dec;73 Suppl 9:257-61. Japanese. PubMed PMID: 26845941.

19: Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. J Comp Eff Res. 2016 May;5(3):273-9. doi: 10.2217/cer.15.69. Epub 2016 Jan 21. PubMed PMID: 26793987.

20: Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016 Jan 14. [Epub ahead of print] PubMed PMID: 26768604.